A study recently published in "Archives of Ophthalmology" examined the possible association of serious risks such as mortality, myocardial infarction, bleeding and stroke with therapies for age-related macular degeneration( AMD).
The research compared photodynamic, pegaptanib, bevacizumab and ranibizumab therapies in a group of 146942 Medicare beneficiaries of 65 years and older with a claim for AMDa between 1 january 2005 and 31 december 2006. It was found that bevacizumaband ranibizumab use was not associated with increased risks of mortality, myocardial infarction, bleeding of stroke compared with photodynamic therapy of pegaptanib use.
No comments:
Post a Comment